Introduction {#s1}
============

Parkinson's disease (PD), a progressive neurodegenerative disorder, is clinically characterized by bradykinesia, rigidity, resting tremor, and postural in-stability \[[@B1]\]. The etiology of the disease remains unclear, although a combination of both genetic and environmental factors are believed to cause PD. The environmental etiology of PD was demonstrated following the discovery that a batch of 'street' heroin contaminated with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) lead to a mimic of idiopathic PD in a group of drug abusers in the early 1980s \[[@B2]\]. On the other hand, several studies have indicated an association between the *CYP2D6* (cytochrome P450, subfamily IID, polypeptide 6; debrisoquine 4-hydroxylase) gene polymorphism and PD in Caucasians \[[@B3]-[@B5]\]. Furthermore, it has been reported that organochlorine insecticides are present at a higher concentration in PD tissues, which may partly explain the association between PD and rural living, and, possibly, between PD and polymorphisms within the *CYP2D6* gene \[[@B6],[@B7]\].

*CYP2D6* is a highly polymorphic member of the cytochrome P450 family located on chromosome 22q13 \[[@B8]\]. The major mutation in *CYP2D6* is the G to A substitution at position 1,934 in the junction of intron3/exon4 (*CYP2D6\*4*), also called the *CYP2D6B* or *CYP2D629B* mutant allele \[[@B9]\]. Polymorphism of this gene causes a frame shift in the mRNA and forms a premature stop codon, resulting in a poorer metabolism of debrisoquine 4-hydroxylase \[[@B10]\]. Therefore, it has been postulated that carriers of the mutant \*4 allele are more susceptible to neurotoxic damage due to the dysfunctional enzyme and consequently have a higher rate of neuronal loss and reach the disease threshold at an earlier age.

The hypothesis toward poorer metabolism of debrisoquine 4-hydroxylase caused by a defect in *CYP2D6* and risk of PD has been studied by a number of authors; however, results remain controversial. Studies by Armstrong et al. \[[@B9]\] and Smith et al. \[[@B11]\] reported that the frequency of mutations in *CYP2D6\*4* confer a two-fold increase in odds ratio (OR) for PD patients compared to healthy control individuals. On the other hand, no significant difference in mutation frequency was found in studies conducted by Plante-Bordeneuve et al. \[[@B12]\] and Atkinson et al. \[[@B13]\]. Determination of this polymorphism, which accounts for the highest frequency of *CYP2D6* mutant alleles (21%) \[[@B14]\], could help identify whether *CYP2D6* polymorphisms denote a susceptibility to developing PD. We therefore performed a systematic review and meta-analysis to quantitatively assess the association between *CYP2D6\*4* allele polymorphism and PD risk.

Methods {#s2}
=======

Search strategy {#s2.1}
---------------

A comprehensive literature search of PubMed, EMBASE, and the China National Knowledge Infrastructure (CNKI) covering all articles published up to September 1, 2013 was conducted using the search strategy based on combinations of the keywords "*cytochrome P450 CYP2D6* OR *CYP2D6*" and "Parkinson OR Parkinson's *disease*" and "*polymorphism*, *mutation* OR *variant*". No language restrictions were applied. The reference lists of relevant articles were checked manually to find additional eligible studies and no attempts were made to identify unpublished studies.

Selection criteria {#s2.2}
------------------

This study was performed according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines for reporting \[[@B15]\]. Inclusion criteria were defined as follows: i) studies evaluating the association between *CYP2D6\*4* allele polymorphism and PD; ii) case-control studies; and iii) studies with sufficient data available to estimate the OR with their 95% confidence intervals (95% CIs). Exclusion criteria included: i) articles without sufficient information for data extraction and ii) articles that only assessed the association between *CYP2D6* and PD in phenotype or other alleles. If dual or multiple studies were reported by the same institution or authors, either the one of higher quality or the most recent study was included in the analysis.

Data extraction {#s2.3}
---------------

Two investigators (Xue Qin and Yu Lu) independently extracted data from the studies included. The following variables were extracted: first author's name, year of publication, country, ethnicity, genotyping method, number of cases and controls, source of controls, genotype distribution in cases and controls and *P* value for control population in Hardy-Weinberg equilibrium (HWE), and the onset age of PD patients as well as the form of the disease (sporadic or familial). If different results were generated, discrepancies were discussed to reach consensus. Considering the subgroup of ethnicity, subjects were grouped into the main racial group of the study population according to their geographical origin or ancestry \[[@B16]\].

Quality assessment {#s2.4}
------------------

To evaluate the quality of the included studies, two investigators (Cuiju Mo and Zhiyu Zeng) assessed them independently based on a set of predetermined criteria which was initially proposed by Thakkinstian et al. \[[@B17]\] and has been in a previous meta-analysis \[[@B18]\] ([Table S2](#pone.0084413.s002){ref-type="supplementary-material"}). The predetermined criteria were scored from 0 (lowest) to 15 (highest) to classify the studies into high or low quality studies. Studies with scores of ≥10 or \<10 were considered as high- and low-quality studies, respectively. Any disagreement was resolved by consensus between the two authors. A third reviewer (Shan Li) was invited to the discussion if disagreement prevailed.

Statistical analysis {#s2.5}
--------------------

For the included studies, summary ORs and corresponding 95% CIs were used as a measure to assess the association of *CYP2D6\*4* allele polymorphism and PD risk. The following contrasts were evaluated: i) a comparison of variant alleles with a wild allele (A vs. G allele); ii) a comparison of each homozygote with the other combined with a heterozygote (AG+AA vs. GG; AA vs. GG+AG); and iii) a comparison of a variant homozygote with a heterozygote and a wild homozygote (AA vs. GG; AG vs. GG). Subgroup analyses were also conducted to evaluate the effect of *CYP2D6\*4* allele polymorphism on the susceptibility to PD in different populations (Asian and Caucasian); different onset age of PD patients (grouped as early onset age (E): [\<]{.ul}51 years old, late onset age (L): \>51 years old; and not available (NA)); and different forms of PD (sporadic (S)/familial (F)/not reported (NR)). The Q test and I^2^ statistics for heterogeneity were carried out for each combined analysis where *P* ~Q~ \<0.10 or I^2^ \>50% indicated significant heterogeneity. If significant heterogeneity existed, a random-effects model (the DerSimonian and Laird method) was selected to pool the data; otherwise, a fixed-effects model (the Mantel-Haenszel method) was used. When heterogeneity was detected, we performed logistic meta-regression to explore the sources of heterogeneity among studies. The following characteristics were included as covariates in the analysis: genotyping methods (PCR-RFLP/not PCR-RFLP), ethnicity (Caucasian/Asian), quality score (high/low), source of controls (hospital-based/not hospital-based), onset age of PD (E/L/NA), and form of the disease (S/F/NR). Galbraith plot analysis was performed for further exploration of the heterogeneity.

To identify possible influential studies, sensitivity analysis was also performed by sequential omission of individual studies, excluding those without definite diagnostic criteria as well as those in which genotype frequencies in control populations exhibited significant deviation from the HWE, given that the deviation may denote bias. HWE in the control group population was tested by using a goodness-of-fit Chisquare test. For each polymorphism, publication bias was evaluated using a funnel plot and Egger's regression asymmetry test (*P* \<0.05 was considered a significant publication bias). All data were analyzed using STATA software version 11.0 (Stata Corp, College Station, TX, USA) and all *P* values were two-sided.

Results {#s3}
=======

Study characteristics {#s3.1}
---------------------

A total of 91 studies were identified; 35 studies that did not focus on *CYP2D6* were excluded after reviewing the title. After a careful abstract and/or full-text review, a further 35 studies were excluded: 15 assessed the association between *CYP2D6* and PD in phenotype or other alleles, 6 without sufficient information to access ORs and 95% CI, 13 were review articles or meta-analyses, and 1 had duplicated data. Thus, 21 relevant studies that focused on *CYP2D6\*4* allele polymorphism and PD risk met the inclusion criteria for the meta-analysis \[[@B9],[@B11]-[@B13],[@B19]-[@B35]\]. The retrieval process is illustrated in [Figure 1](#pone-0084413-g001){ref-type="fig"}. Among the eligible studies, one contained data on two different forms of the disease (sporadic and familial) \[[@B28]\], and the results were therefore treated independently. Consequently, 22 separate comparisons consisting of 2,629 patients and 3,601 controls were finally included in the meta-analysis. The main characteristics of the studies are presented in [Table 1](#pone-0084413-t001){ref-type="table"}. Of all the eligible studies, 15 were conducted in Caucasians and 6 in Asians; 4 studied PD patients with early onset age and 5 with late onset age; and 13 were conducted in sporadic patients and 6 in familial patients. The genotype distributions of the controls in 4 studies were not consistent with HWE. Sixteen studies had quality scores of [\>]{.ul}10 and the rest of \<10. Details are presented in [Table 2](#pone-0084413-t002){ref-type="table"}.

![Flow diagram for the selection of articles for inclusion in the meta-analysis.](pone.0084413.g001){#pone-0084413-g001}
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###### Characteristics of studies included in this meta-analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, Year             country             Ethnicity    case/control     Genotyping methods     Form of PD patients(S/F/NR)     PD on-set age(E/L/NA)                      Source of control   PI               HWE(P value)   QS
  ------------------------ ------------------- ------------ ---------------- ---------------------- ------------------------------- ------------------------------------------ ------------------- ---------------- -------------- ----
  Smith CA,1992            UK                  Caucasian    193/720          PCR                    S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.106          12

  Armstrong M,1992         UK                  Caucasian    53/72            PCR-RFLP               NR                              NA                                         H-B                 CYP2D6-B         0.174          10

  Kurth MC,1993            USA                 Caucasian    50/110           PCR-RFLP               F                               L                                          H-B                 CYP2D6-29B       0.178          10

  Plante-Bordeneuve,1994   British and Irish   Caucasian    45/69            PCR                    F                               NA                                         H-B                 CYP2D6-B         0.215          10

  Akhmedova SN,1995        Russia              Caucasian    80/70            PCR-RFLP               S                               NA                                         F-B                 CYP2D6-29B       0.886          9

  Agundez JA,1995          Spain               Caucasian    123/150          PCR-RFLP               NR                              33/123 E: 39.4±7.2y 90/123 L: 65.9±8.0y    P-B                 CYP2D6-B         0.552          11

  Diederich N,1996         Germany             Caucasian    80/106           PCR                    S                               32/80 E: 39.8±5.1y 48/80 L: 63.2±7.7y      Mix                 CYP2D6-B         0.014          7

  Gasser T,1996            diverse             Caucasian    178/73           PCR                    115/178 S 63/178 F              NA                                         H-B                 CYP2D6-B         0.901          10

  Chen X,1996              guam                Oriental\    28/212           PCR                    S                               NA                                         H-B                 CYP2D6-B         0.033          7
                                               population                                                                                                                                                                          

  Bordet R,1996            France              Caucasian    105/105          PCR-RFLP               S                               NA                                         H-B                 CYP2D6-B         0.065          10

  Pang CP,1997             China               Asian        200/227          PCR                    S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.925          11

  Chen DK,1998             China               Asian        215/313          PCR                    S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.936          11

  Nicholl,1999             UK                  Caucasian    176/175          PCR-RFLP               S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.066          10

  Nicholl,1999             UK                  Caucasian    30/30            PCR-RFLP               F                               NA                                         H-B                 CYP2D6\*4 G\>A   0.110          9

  Atkinson A,1999          UK                  Caucasian    33/75            PCR-RFLP               S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.019          8

  Chida M,1999             Japan               Asian        38/270           PCR                    S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.862          10

  Joost O,1999             USA                 Caucasian    109/110          PCR                    NR                              NA                                         H-B                 CYP2D6\*4 G\>A   0.618          10

  Štefanovć M,2000         Croatia             Caucasian    41/145           LR-PCR                 NR                              NA                                         H-B                 CYP2D6\*4 G\>A   0.495          10

  PayamiH,2001             USA                 Caucasian    576/247          PCR                    360/576 S 162/576 F             145/576E: 41.1±7.8y 431/576 L: 63.1±7.7y   H-B                 CYP2D6\*4 G\>A   0.004          9

  Woo SI,2001              Korea               Asian        93/122           PCR                    NR                              NA                                         H-B                 CYP2D6\*4 G\>A   0.945          10

  Durić G,2007             Russia              Caucasian    106/75           PCR--RFLP              96/106 S 10/106 F               55/106 E: 39.5±3.8y 41/106 L: 58.1±6.2y    H-B                 CYP2D6\*4 G\>A   0.281          11

  Singh M,2010             India               Asian        77/125           PCR--RFLP              S                               NA                                         H-B                 CYP2D6\*4 G\>A   0.059          11
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PI, Polymorphism(s) investigated; PCR--RFLP, Polymerase chain reaction-restriction fragment length polymorphism; RT--PCR, Real time-polymerase chain reaction; LR-PCR, long-range-PCR; NR: Not report; NA, Not available; PB, Population--based; HB, Hospital--based; HWE, Hardy--Weinberg equilibrium in control population; QS: quality score

10.1371/journal.pone.0084413.t002

###### Meta-analysis and heterogeneity test of the CYP2D6 gene polymorphisms on PD risk.

  Comparisons                    No. of study   No. of patient   A vs. G           AA vs. GG   AG vs. GG         AG + AA vs. GG   AA vs. AG + GG                                                      
  ------------------------------ -------------- ---------------- ----------------- ----------- ----------------- ---------------- ----------------- ------ ----------------- ------ ----------------- ------
  overall                        22             2629             1.28(1.14-1.43)   38.7        1.43(1.06-1.93)   0.0              1.22(1.06-1.40)   29.8   1.26(1.10-1.44)   23.1   1.37(1.02-1.83)   0.0
  subgroup                                                                                                                                                                                            
  Sporadic/Familial PD(S/F/NR)                                                                                                                                                                        
  S                              13             1932             1.15(1.00-1.32)   17.6        1.40(1.00-1.96)   11.0             1.06(0.89-1.25)   13.4   1.11(0.95-1.30)   0.0    1.37(0.98-1.92)   21.0
  F                              6              278              1.40(1.04-1.88)   74.1        1.13(0.56-2.29)   26.4             1.50(1.04-2.16)   58.1   1.44(1.02-2.03)   64.6   1.33(1.00-1.78)   2.7
  NA                             5              419              1.65(1.24-2.20)   23.4        1.80(0.71-4.59)   9.5              1.62(1.17-2.26)   0.0    1.65(1.19-2.27)   0.0    1.61(0.64-4.08)   3.9
  Early/Late-onset PD(E/L/NA)                                                                                                                                                                         
  E                              4              265              0.84(0.62-1.14)   85.1        0.60(0.28-1.27)   0.0              0.97(0.67-1.41)   80.8   0.90(0.63-1.28)   81.1   0.66(0.32-1.50)   0.0
  L                              5              660              1.15(0.93-1.42)   74.4        0.87(0.52-1.47)   37.8             1.28(0.98-1.66)   34.6   1.20(0.94-1.54)   55.2   0.80(0.48-1.33)   5.9
  NA                             16             1694             1.32(1.14-1.53)   33.9        1.67(1.14-2.45)   0.0              1.23(1.03-1.46)   31.9   1.28(1.09-1.52)   24.5   1.61(1.10-2.34)   0.0
  Ethnicity                                                                                                                                                                                           
  Asian                          6              651              1.26(0.78-2.03)   0.0         1.08(0.21-5.47)   0.0              1.31(0.77-2.23)   0.0    1.27(0.76-2.13)   0.0    1.05(0.21-5.28)   0.0
  Caucasian                      15             1978             1.28(1.13-1.44)   50.2        1.45(1.07-1.96)   0.3              1.21(1.05-1.40)   39.4   1.26(1.09-1.44)   33.4   1.38(1.02-1.86)   1.4

OR: odds ratio; CI: confidence intervals; S/F/NR: Sporadic/Familial/Not Report; E/L/NA: Early/Late/Not Available.

Meta-analysis results {#s3.2}
---------------------

The pooled analysis suggested that the *CYP2D6\*4* allele polymorphism was significantly associated with an increased risk of PD in all genetic models in the overall population: i) A vs. G allele (OR = 1.28, 95% CI = 1.14--1.43, *P* = 0.001); ii) AA vs. GG (OR = 1.43, 95% CI = 1.06--1.93, *P* = 0.018); iii) AG vs. GG (OR = 1.22, 95% CI = 1.06--1.40, *P* = 0.006); iv) AG+AA vs. GG (OR = 1.26, 95% CI = 1.10--1.44, *P* = 0.001); and v) AA vs. AG+GG (OR = 1.37, 95% CI = 1.02--1.83, *P* = 0.036). In the subgroup analysis stratified by ethnicity, the results also showed a significant contribution of the *CYP2D6\*4* allele polymorphism to PD development in the Caucasian population in all of the comparisons of the A vs. G allele (OR = 1.28, 95% CI = 1.13--1.44, *P* = 0.001); AA vs. GG (OR = 1.45, 95% CI = 1.07--1.96, *P* = 0.017); AG vs. GG (OR = 1.21, 95% CI = 1.05--1.40, *P* = 0.009); AG+AA vs. GG (OR = 1.26, 95% CI = 1.09--1.44, *P* = 0.001); and AA vs. AG+GG (OR = 1.37, 95% CI = 1.02--1.86, *P* = 0.034). When stratified by form of the disease, a significantly increased risk was found in all forms of the disease, indicating that susceptibility to PD due to *CYP2D6\*4* allele polymorphism may be independent from the form of PD onset. Similarly, a significantly increased risk was found only in the "Not available" group when stratified by PD onset age, suggesting that *CYP2D6\*4* allele mutations are independent from onset age. The details are presented in [Table 1](#pone-0084413-t001){ref-type="table"}.

Heterogeneity analysis {#s3.3}
----------------------

For the A vs. G comparison model, the I^2^ value of heterogeneity was lower than 50% and the P~Q~ value was lower than 0.10 (I^2^=37.8%, *P* ~Q~= 0.034), indicating a statistically significant heterogeneity among studies. To explore the sources of heterogeneity, we performed meta-regression analyses. The results showed that none of the factors mentioned above were effect modifiers: genotyping methods (*P* = 0.873), ethnicity (*P* = 0.853), quality score (*P* = 0.292), source of controls (*P* = 0.166), onset age of PD (*P* = 0.423), and form of the disease (*P* = 0.948). To further investigate the heterogeneity, Galbraith plots analysis was performed to identify the outliers that might contribute to the heterogeneity. Our results showed that the studies by Kurth et al. \[[@B19]\] and Atkinson et al. \[[@B13]\] were the outliers and main contributors to heterogeneity in this comparison model ([Figure 2a](#pone-0084413-g002){ref-type="fig"}). A forest plot omitting the outlier studies was conducted, the significance of the OR was not altered (OR = 1.21, 95% CI = 1.08--1.37, *P* = 0.001) and was without evidence of heterogeneity (I^2^ = 18.0%, P~Q~ = 0.230) in the overall populations as well as in subgroup analysis of the Caucasian population (OR = 1.21, 95% CI = 1.07--1.37, *P* = 0.002, I^2^ = 31.5%, *P* ~Q~ = 0.124). However, results remained the same in the other subgroup analyses.

![Galbraith plots of CYP2D6\*4 allele polymorphisms and PD risk in different contrast models.\
a The studies of Kurth MC et al. and Atkinson A et al. were outliers in the contrast A vs. G. b The studiy of Atkinson A et al. was the outlier in the contrast AG vs. GG. c The studies of Atkinson A et al. was the outlier in the contrast AG+AA vs. GG.](pone.0084413.g002){#pone-0084413-g002}

For the remaining comparison models, there was no statistically significant heterogeneity in the overall population. However, subgroup analysis by onset age and form of the disease indicated significant heterogeneity in the AG vs. GG and AG+AA vs. GG models. When the Galbraith plot was analyzed, the study by Atkinson et al. \[[@B13]\] was identified as the main contributor to heterogeneity ([Figure 2b,c](#pone-0084413-g002){ref-type="fig"}); however, after exclusion of the study, heterogeneity still existed among studies in the two genetic comparison models mentioned above (data not show).

Sensitivity analysis {#s3.4}
--------------------

As the genotype frequencies of the control group in 4 studies deviated significantly from HWE \[[@B13],[@B23],[@B25],[@B32]\] ([Table 2](#pone-0084413-t002){ref-type="table"}), the influence of each study involved in the meta-analysis of the pooled ORs was examined by rerunning the meta-analysis with one study excluded each time. Results showed that the corresponding pooled ORs were not significantly altered (data not shown), indicating that our results were statistically robust.

Publication bias {#s3.5}
----------------

Begg's funnel plot and Egger's test were performed to assess the publication bias of articles in all comparison models. The shape of the funnel plots were symmetrical, suggesting that there was no evidence of publication bias among the studies. Egger's test was also used to statistically assess the funnel plot symmetry. The results still did not suggest any evidence of publication bias in all comparison models ([Figure 3](#pone-0084413-g003){ref-type="fig"}).

![Funnel plot analysis and Egger's test to detect publication bias in different contrast models.\
Each point represents a separate study for the indicated association. a Funnel plot and Egger's test for contrast A vs. G; b Funnel plot and Egger's test for contrast AA vs. GG; c Funnel plot and Egger's test for contrast AG vs. GG; d Funnel plot and Egger's test for contrast AG+AA vs. GG; e Funnel plot and Egger's test for contrast AA vs. GG+AG.](pone.0084413.g003){#pone-0084413-g003}

Discussion {#s4}
==========

*CYP2D6* is a member of the cytochrome P450 gene family, which plays an important role in the metabolism of many substances \[[@B8]\]. It has been reported that *CYP2D6* is expressed constitutively in human liver and metabolizes a variety of therapeutic drugs, including antiarrhythmics, antidepressants, and neuroleptics \[[@B36]\]. Evidence that *CYP2D6* can metabolize environmental toxins such as the neurotoxins 1,2,3,4-tetrahydroisoquinoline and MPTP has also been found \[[@B37],[@B38]\]. A common variation in the *CYP2D6* gene is a G to A shift in exon4, which results in substitution of Glu for Gly \[[@B39]\], and is associated with reduced *CYP2D6* activity. Decreased *CYP2D6* activity may lead to an alteration of susceptibility to neurotoxic damage and a higher rate of neuronal loss, thus making carriers more susceptible to PD; this hypothesis was confirmed by the present meta-analysis.

In our study, a significantly increased risk of PD was associated with the *CYP2D6\*4A* allele in the overall population and in Caucasians in particular, suggesting that individuals with the mutated *CYP2D6\*4* genotype had higher risk of PD compared to those with wild type, especially among the Caucasian population. However, no association was detected among the Asian population. Indeed, it is common for the same polymorphism to play different roles in disease susceptibility among different ethnic populations. This may be principally explained by the *CYP2D6* genetic background difference between such populations \[[@B40]\]; using allele-specific PCR, approximately 100 Caucasian subjects were screened for the presence of *CYP2D6\*4G/A* mutation, but in the original population studied, the mutation was only detected in one individual \[[@B39]\]. Further, multiple environmental factors, such as diet, residence in rural areas, and exposure to pesticides, that may be involved in the mechanism linking *CYP2D6* genotype and the risk of developing PD vary between ethnic groups \[[@B41]\]. Finally, considering the limited number of Asian-patient studies included in the meta-analysis (Asian patients = 651, Caucasian patients = 1,978), the differences may have arisen by chance. Hence, our results should be interpreted with caution.

In the subgroup analysis based on form of the disease, a significantly increased risk was found for all forms of the disease (familial, sporadic, not reported), suggesting that the presence of *CYP2D6\*4* polymorphism leading to poor debrisoquine metabolism is associated with an increased risk for PD regardless of the patient's family history. However, there is considerable variation in the frequencies of mutant *CYP2D6* alleles in familial and sporadic PD of different populations \[[@B11],[@B22],[@B42],[@B43]\]. Nevertheless, the majority of studies included in our subgroup analysis did not reveal any significant association between *CYP2D6* mutations and familial PD \[[@B12],[@B19],[@B22],[@B32],[@B34]\]. Such discrepancy is probably not the result of population bias but likely the involvement of a multitude of genetic and environmental factors because there is no evidence of clinical or histological difference in PD in different populations \[[@B22]\].

In a further subgroup analysis restricted to the onset age of PD patients, no significant increased risk was found in patients with early or late onset age, suggesting that the early-onset PD patients share the same genetic background as the late-onset PD patients and there might be not any different pathogenetic mechanisms involved in onset age of PD patients. It has been reported that the frequency of \*4 allele is significantly elevated in late-onset as compared with early-onset PD, but similar trend was also found in non-PD populations \[[@B32]\]. Therefore, the difference in \*4 allele frequency between early- and late-onset PD observed by some studies was probably due to an age effect but does not necessarily signify an association with disease.

This meta-analysis should be considered with its limitations. First, the *CYP2D6* phenotypes were not studied. Genetic polymorphism of *CYP2D6* is inherited as an autosomal recessive trait, with more than 60 alleles known thus far (http://www.cypalleles.ki.se/). These alleles, occurring in various combinations or along with other alleles, result in three phenotypes: extensive metabolizer, intermediate metabolizer, and poor metabolizer \[[@B44],[@B45]\]. Determination of these phenotypes, which contain all genetic polymorphisms of *CYP2D6*, can comprehensively and directly access the relationship between *CYP2D6* polymorphism and PD risk. Second, the overall outcomes of our study were based on individual unadjusted ORs, but a more precise evaluation should be adjusted by potentially suspected factors such as age, gender, and environmental factors. Such a problem was observed in a meta-analysis conducted by Rostami et al. \[[@B46]\], where a marginally higher poor metabolizer phenotype frequency in patients was found, but the ORs dropped to 1 when studies that did not match patients and control subjects for age were excluded. Some studies included in our meta-analysis also did not use subjects matched for age or environmental factors; the results would hence underestimate the association of OR with genotype. Third, the controls were not uniformly defined. Though most of the controls were selected mainly from healthy populations, there are some were unaffected relatives with a positive family history or benign disease such as chronic bronchitis was included \[[@B22],[@B24]\]. Hence, as these studies may have included individuals with different risks of developing PD in their control groups, a non-differential misclassification bias was possible. Fourth, the number of studies on *CYP2D6\*4* polymorphism in the Asian population included in this study was relatively small, which may lead to low statistical power. Finally, publication bias was possible as no attempts were made to identify unpublished studies, though results of our Begg's funnel plot and Egger's test revealed no evidence of publication bias in all comparison models.

In conclusion, the present meta-analysis clearly indicates that the *CYP2D6\*4G/A* polymorphism denotes an increased genetic susceptibility to PD in the overall population, but particularly in Caucasians. However, larger sample studies with a more rigorous design and well-matched controls are required to overcome the above-mentioned limitations, especially investigations taking the other allele polymorphisms of *CYP2D6* as well as phenotype status into consideration.
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